This section focuses on the clinical decision making process following progression on lanreotide and lutetium Lu 177 dotatate. Dr Shaheen outlines how she approaches next line therapy selection in a ...

Clinical outcomes of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs everolimus (EVE) in managing patients (pts) with gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): Real-world analysis of the PRIME ...

Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) demonstrate a somatostatin receptor-expressing meningioma in the left cavernous ...

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

J. Bart Rose, M.D., MAS., an associate professor in the UAB Department of Surgery, joined UAB MedCast to discuss the complexity of neuroendocrine tumors (NETs) and the use of peptide receptor ...

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation Of 37 patients enrolled, ...

Sanofi (NASDAQ:SNY) announced on Wednesday that its experimental cancer therapy, AlphaMedix, developed in collaboration with partner Orano Med, has succeeded in a mid-stage trial for certain patients ...